Targeting ROR1 by small molecules and mAbs has been shown to be an effective therapeutic approach in pre-clinical and clinical studies in various malignancies, such as CLL, MCL, lung, breast cancers, etc. [27,43,46,67,71]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.